Accretion Pharmaceuticals Limited H1 FY26 Concall Decoded:Revenue went vertical, margins took a breather, and management basically said—relax, registrations aren’t free.
Fresh IPO glow, first concall nerves, and a lot of confidence packed into one call—Accretion Pharmaceuticals made its debut like a pharma startup that suddenly discovered scale. After listing on NSE Emerge in May, the company showed up with triple-digit growth, Africa-heavy ambitions, and enough acronyms (CDMO, GMP, WHO) to keep analysts awake.
Revenue exploded, profits followed, but margins… well, they decided to sit this quarter out. Management blamed registrations, scale-up costs, and the classic “growth phase” excuse that every expanding pharma company swears by.
The story sounds familiar, but the pace is not. Over 100 product registrations, presence in 30+ countries, and a 40% capacity expansion—all in one breath.
Stick around. The numbers look flashy, but the real masala is in what they didn’t commit to later.
2. At a Glance
Revenue ₹43.74 cr (+136%) – IPO cash clearly knew where the machines were.
EBITDA ₹7.07 cr (+63%) – Growth came fast, margins asked for a break.
EBITDA margin 16.2% – Down from ~23%; regulators don’t work for free.
PAT ₹4.75 cr (+93%) – Profits grew, just not at startup speed.
ROCE 38% (FY25) – Capital sweating harder than analysts on guidance questions.
Capacity +40% – Assets upgraded, utilization still warming up.
3. Management’s Key Commentary
“We are interacting with capital markets for the first time after listing.” (Translation: Please go easy, this is our first concall 😏)
“Revenue growth was driven by IPO-funded capex and capacity utilization.” (Translation: Money + machines = magic.)
“Africa has always been a key focus geography.” (Translation: Faster approvals, real volumes, fewer headaches.)
“Margins declined due to product registration and scale-up expenses.” (Translation: Growth noticed your EBITDA and sat on it.)
“Over 100 products are under registration across multiple countries.” (Translation: Pipeline is full, execution calendar is packed.)
“We expect the same momentum going forward.” (Translation: Please don’t force us to give numbers 🙃)
